Edison Investment Research - GeoVax (GOVX) QuickView: Q314 NIH funding decision could be key

Report

Edison Investment Research

QuickView: Q314 NIH funding decision could be key

GeoVax provided an update on its lead programmes with the recent Q214 financial results. The next development steps for GOVX-B11 are subject to US NIH funding and a decision, expected in Q314, to fund production of a key component of the vaccine for further trials could be indicative of future support. GeoVax is also working on the elements required for an HIV immunotherapy, with a Phase I/II trial currently being planned.

14/08/2014 2 EN

Underlying

GeoVax

See profile

United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: Termination of Coverage

Edison Investment Research is terminating coverage on GeoVax (GOVX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

January 7, 2015 January 7, 2015 1 EN

Edison Investment Research

QuickView: Focused on HIV immunotherapy and Ebola

GeoVax continues to focus on advancing both its HIV immunotherapy programme and Ebola vaccines, which will require additional funding. Further development of the GOVX-B11 preventative HIV vaccine remains under consideration by the US NIH, although a large Phase IIb trial in 2015 now seems unlikely as HVTN reconsiders the merits of adding a protein boost. The exercise of certain warrants has increased cash to c $1.7m.

November 18, 2014 November 18, 2014 2 EN

Edison Investment Research

QuickView: Leveraging technology for Ebola

GeoVax has announced plans to develop two Ebola vaccines, one for the strain responsible for the current outbreak and a preventative vaccine against multiple strains for the future. GeoVax plans to construct the MVA vectors using its recombinant MVA vaccine platform ready for preclinical testing, for which additional funds are likely to be needed. These could potentially come from government sources, or from the capital markets.

October 6, 2014 October 6, 2014 2 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Q314 NIH funding decision could be key

Update: Termination of Coverage

QuickView: Focused on HIV immunotherapy and Ebola

QuickView: Leveraging technology for Ebola

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe